According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Hosted on MSN20h
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same PageShares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...
On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...
Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...
Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...
News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...
LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback